nodes	percent_of_prediction	percent_of_DWPC	metapath
Trametinib—CYP2C8—Sorafenib—thyroid cancer	0.0562	0.43	CbGbCtD
Trametinib—CYP3A4—Vandetanib—thyroid cancer	0.0378	0.29	CbGbCtD
Trametinib—CYP3A4—Sorafenib—thyroid cancer	0.0228	0.175	CbGbCtD
Trametinib—CYP3A4—Doxorubicin—thyroid cancer	0.0138	0.106	CbGbCtD
Trametinib—MAP2K1—neck—thyroid cancer	0.00525	0.289	CbGeAlD
Trametinib—MAP2K2—saliva-secreting gland—thyroid cancer	0.00361	0.199	CbGeAlD
Trametinib—MAP2K1—head—thyroid cancer	0.00222	0.122	CbGeAlD
Trametinib—MAP2K2—thyroid gland—thyroid cancer	0.0022	0.121	CbGeAlD
Trametinib—MAP2K2—head—thyroid cancer	0.00195	0.108	CbGeAlD
Trametinib—MAP2K1—lymph node—thyroid cancer	0.00155	0.0856	CbGeAlD
Trametinib—MAP2K2—lymph node—thyroid cancer	0.00137	0.0753	CbGeAlD
Trametinib—Epistaxis—Sorafenib—thyroid cancer	0.00105	0.00254	CcSEcCtD
Trametinib—Infection—Vandetanib—thyroid cancer	0.00104	0.00253	CcSEcCtD
Trametinib—Nervous system disorder—Vandetanib—thyroid cancer	0.00103	0.00249	CcSEcCtD
Trametinib—Thrombocytopenia—Vandetanib—thyroid cancer	0.00103	0.00249	CcSEcCtD
Trametinib—Skin disorder—Vandetanib—thyroid cancer	0.00102	0.00247	CcSEcCtD
Trametinib—Cyst—Doxorubicin—thyroid cancer	0.00102	0.00246	CcSEcCtD
Trametinib—Haemoglobin—Sorafenib—thyroid cancer	0.001	0.00243	CcSEcCtD
Trametinib—Haemorrhage—Sorafenib—thyroid cancer	0.000998	0.00241	CcSEcCtD
Trametinib—Vaginal haemorrhage—Epirubicin—thyroid cancer	0.000992	0.0024	CcSEcCtD
Trametinib—Urinary tract disorder—Sorafenib—thyroid cancer	0.000986	0.00238	CcSEcCtD
Trametinib—Connective tissue disorder—Sorafenib—thyroid cancer	0.000981	0.00237	CcSEcCtD
Trametinib—Urethral disorder—Sorafenib—thyroid cancer	0.000978	0.00237	CcSEcCtD
Trametinib—Hypercalcaemia—Doxorubicin—thyroid cancer	0.000978	0.00237	CcSEcCtD
Trametinib—Rash erythematous—Epirubicin—thyroid cancer	0.000959	0.00232	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.000958	0.00232	CcSEcCtD
Trametinib—Insomnia—Vandetanib—thyroid cancer	0.000951	0.0023	CcSEcCtD
Trametinib—Cardiac disorder—Sorafenib—thyroid cancer	0.000926	0.00224	CcSEcCtD
Trametinib—Rash pustular—Epirubicin—thyroid cancer	0.000921	0.00223	CcSEcCtD
Trametinib—Vaginal haemorrhage—Doxorubicin—thyroid cancer	0.000918	0.00222	CcSEcCtD
Trametinib—Decreased appetite—Vandetanib—thyroid cancer	0.000914	0.00221	CcSEcCtD
Trametinib—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.000908	0.0022	CcSEcCtD
Trametinib—Fatigue—Vandetanib—thyroid cancer	0.000906	0.00219	CcSEcCtD
Trametinib—Angiopathy—Sorafenib—thyroid cancer	0.000906	0.00219	CcSEcCtD
Trametinib—Mediastinal disorder—Sorafenib—thyroid cancer	0.0009	0.00218	CcSEcCtD
Trametinib—Constipation—Vandetanib—thyroid cancer	0.000899	0.00217	CcSEcCtD
Trametinib—Arrhythmia—Sorafenib—thyroid cancer	0.000892	0.00216	CcSEcCtD
Trametinib—Rash erythematous—Doxorubicin—thyroid cancer	0.000888	0.00215	CcSEcCtD
Trametinib—Mental disorder—Sorafenib—thyroid cancer	0.000874	0.00212	CcSEcCtD
Trametinib—Malnutrition—Sorafenib—thyroid cancer	0.000869	0.0021	CcSEcCtD
Trametinib—Erythema—Sorafenib—thyroid cancer	0.000869	0.0021	CcSEcCtD
Trametinib—Neoplasm malignant—Epirubicin—thyroid cancer	0.00086	0.00208	CcSEcCtD
Trametinib—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00086	0.00208	CcSEcCtD
Trametinib—Rash pustular—Doxorubicin—thyroid cancer	0.000852	0.00206	CcSEcCtD
Trametinib—Dysgeusia—Sorafenib—thyroid cancer	0.000851	0.00206	CcSEcCtD
Trametinib—Muscle spasms—Sorafenib—thyroid cancer	0.000835	0.00202	CcSEcCtD
Trametinib—Abdominal pain—Vandetanib—thyroid cancer	0.000831	0.00201	CcSEcCtD
Trametinib—Body temperature increased—Vandetanib—thyroid cancer	0.000831	0.00201	CcSEcCtD
Trametinib—Rectal haemorrhage—Epirubicin—thyroid cancer	0.000813	0.00197	CcSEcCtD
Trametinib—Bone disorder—Epirubicin—thyroid cancer	0.000813	0.00197	CcSEcCtD
Trametinib—Cellulitis—Epirubicin—thyroid cancer	0.000808	0.00195	CcSEcCtD
Trametinib—Hyperbilirubinaemia—Epirubicin—thyroid cancer	0.000808	0.00195	CcSEcCtD
Trametinib—Anaemia—Sorafenib—thyroid cancer	0.000803	0.00194	CcSEcCtD
Trametinib—Hypocalcaemia—Epirubicin—thyroid cancer	0.000802	0.00194	CcSEcCtD
Trametinib—Neoplasm malignant—Doxorubicin—thyroid cancer	0.000796	0.00193	CcSEcCtD
Trametinib—Leukopenia—Sorafenib—thyroid cancer	0.000778	0.00188	CcSEcCtD
Trametinib—Creatinine increased—Epirubicin—thyroid cancer	0.000772	0.00187	CcSEcCtD
Trametinib—Cough—Sorafenib—thyroid cancer	0.000758	0.00183	CcSEcCtD
Trametinib—Asthenia—Vandetanib—thyroid cancer	0.000754	0.00182	CcSEcCtD
Trametinib—Rectal haemorrhage—Doxorubicin—thyroid cancer	0.000752	0.00182	CcSEcCtD
Trametinib—Bone disorder—Doxorubicin—thyroid cancer	0.000752	0.00182	CcSEcCtD
Trametinib—Hypertension—Sorafenib—thyroid cancer	0.00075	0.00181	CcSEcCtD
Trametinib—Cellulitis—Doxorubicin—thyroid cancer	0.000747	0.00181	CcSEcCtD
Trametinib—Hyperbilirubinaemia—Doxorubicin—thyroid cancer	0.000747	0.00181	CcSEcCtD
Trametinib—Pruritus—Vandetanib—thyroid cancer	0.000744	0.0018	CcSEcCtD
Trametinib—Hypocalcaemia—Doxorubicin—thyroid cancer	0.000742	0.0018	CcSEcCtD
Trametinib—Arthralgia—Sorafenib—thyroid cancer	0.00074	0.00179	CcSEcCtD
Trametinib—Myalgia—Sorafenib—thyroid cancer	0.00074	0.00179	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.000735	0.00178	CcSEcCtD
Trametinib—Phosphatase alkaline increased—Epirubicin—thyroid cancer	0.000735	0.00178	CcSEcCtD
Trametinib—Dry mouth—Sorafenib—thyroid cancer	0.000723	0.00175	CcSEcCtD
Trametinib—Hyperkalaemia—Epirubicin—thyroid cancer	0.000722	0.00175	CcSEcCtD
Trametinib—Diarrhoea—Vandetanib—thyroid cancer	0.000719	0.00174	CcSEcCtD
Trametinib—Melaena—Epirubicin—thyroid cancer	0.000718	0.00174	CcSEcCtD
Trametinib—Creatinine increased—Doxorubicin—thyroid cancer	0.000714	0.00173	CcSEcCtD
Trametinib—Infection—Sorafenib—thyroid cancer	0.000704	0.0017	CcSEcCtD
Trametinib—Nervous system disorder—Sorafenib—thyroid cancer	0.000695	0.00168	CcSEcCtD
Trametinib—Dizziness—Vandetanib—thyroid cancer	0.000695	0.00168	CcSEcCtD
Trametinib—Thrombocytopenia—Sorafenib—thyroid cancer	0.000694	0.00168	CcSEcCtD
Trametinib—Skin disorder—Sorafenib—thyroid cancer	0.000689	0.00167	CcSEcCtD
Trametinib—Phosphatase alkaline increased—Doxorubicin—thyroid cancer	0.00068	0.00164	CcSEcCtD
Trametinib—Dry eye—Epirubicin—thyroid cancer	0.000678	0.00164	CcSEcCtD
Trametinib—Vomiting—Vandetanib—thyroid cancer	0.000668	0.00162	CcSEcCtD
Trametinib—Hyperkalaemia—Doxorubicin—thyroid cancer	0.000668	0.00162	CcSEcCtD
Trametinib—Rash maculo-papular—Epirubicin—thyroid cancer	0.000668	0.00162	CcSEcCtD
Trametinib—Neoplasm—Epirubicin—thyroid cancer	0.000664	0.00161	CcSEcCtD
Trametinib—Mouth ulceration—Epirubicin—thyroid cancer	0.000664	0.00161	CcSEcCtD
Trametinib—Melaena—Doxorubicin—thyroid cancer	0.000664	0.00161	CcSEcCtD
Trametinib—Rash—Vandetanib—thyroid cancer	0.000663	0.0016	CcSEcCtD
Trametinib—Dermatitis—Vandetanib—thyroid cancer	0.000662	0.0016	CcSEcCtD
Trametinib—Headache—Vandetanib—thyroid cancer	0.000659	0.00159	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.000646	0.00156	CcSEcCtD
Trametinib—Dry eye—Doxorubicin—thyroid cancer	0.000628	0.00152	CcSEcCtD
Trametinib—Nausea—Vandetanib—thyroid cancer	0.000624	0.00151	CcSEcCtD
Trametinib—Rash maculo-papular—Doxorubicin—thyroid cancer	0.000618	0.00149	CcSEcCtD
Trametinib—Decreased appetite—Sorafenib—thyroid cancer	0.000616	0.00149	CcSEcCtD
Trametinib—Mouth ulceration—Doxorubicin—thyroid cancer	0.000615	0.00149	CcSEcCtD
Trametinib—Neoplasm—Doxorubicin—thyroid cancer	0.000615	0.00149	CcSEcCtD
Trametinib—Blood alkaline phosphatase increased—Epirubicin—thyroid cancer	0.000613	0.00148	CcSEcCtD
Trametinib—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000612	0.00148	CcSEcCtD
Trametinib—Fatigue—Sorafenib—thyroid cancer	0.000611	0.00148	CcSEcCtD
Trametinib—Constipation—Sorafenib—thyroid cancer	0.000606	0.00147	CcSEcCtD
Trametinib—Cardiac failure congestive—Epirubicin—thyroid cancer	0.000588	0.00142	CcSEcCtD
Trametinib—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00058	0.0014	CcSEcCtD
Trametinib—Renal failure acute—Epirubicin—thyroid cancer	0.000578	0.0014	CcSEcCtD
Trametinib—Blood alkaline phosphatase increased—Doxorubicin—thyroid cancer	0.000567	0.00137	CcSEcCtD
Trametinib—Body temperature increased—Sorafenib—thyroid cancer	0.000561	0.00136	CcSEcCtD
Trametinib—Abdominal pain—Sorafenib—thyroid cancer	0.000561	0.00136	CcSEcCtD
Trametinib—Cardiac failure congestive—Doxorubicin—thyroid cancer	0.000544	0.00132	CcSEcCtD
Trametinib—Hyponatraemia—Epirubicin—thyroid cancer	0.000535	0.0013	CcSEcCtD
Trametinib—Renal failure acute—Doxorubicin—thyroid cancer	0.000534	0.00129	CcSEcCtD
Trametinib—Pain in extremity—Epirubicin—thyroid cancer	0.000533	0.00129	CcSEcCtD
Trametinib—Asthenia—Sorafenib—thyroid cancer	0.000509	0.00123	CcSEcCtD
Trametinib—Pruritus—Sorafenib—thyroid cancer	0.000502	0.00121	CcSEcCtD
Trametinib—Blood creatinine increased—Epirubicin—thyroid cancer	0.0005	0.00121	CcSEcCtD
Trametinib—Dehydration—Epirubicin—thyroid cancer	0.000496	0.0012	CcSEcCtD
Trametinib—Hyponatraemia—Doxorubicin—thyroid cancer	0.000495	0.0012	CcSEcCtD
Trametinib—Pain in extremity—Doxorubicin—thyroid cancer	0.000493	0.00119	CcSEcCtD
Trametinib—Dry skin—Epirubicin—thyroid cancer	0.000489	0.00118	CcSEcCtD
Trametinib—Abdominal pain upper—Epirubicin—thyroid cancer	0.000487	0.00118	CcSEcCtD
Trametinib—Hypokalaemia—Epirubicin—thyroid cancer	0.000485	0.00117	CcSEcCtD
Trametinib—Diarrhoea—Sorafenib—thyroid cancer	0.000485	0.00117	CcSEcCtD
Trametinib—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	0.00048	0.00116	CcSEcCtD
Trametinib—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.00047	0.00114	CcSEcCtD
Trametinib—Dizziness—Sorafenib—thyroid cancer	0.000469	0.00113	CcSEcCtD
Trametinib—Blood creatinine increased—Doxorubicin—thyroid cancer	0.000462	0.00112	CcSEcCtD
Trametinib—Dehydration—Doxorubicin—thyroid cancer	0.000459	0.00111	CcSEcCtD
Trametinib—Dry skin—Doxorubicin—thyroid cancer	0.000452	0.00109	CcSEcCtD
Trametinib—Pancreatitis—Epirubicin—thyroid cancer	0.000452	0.00109	CcSEcCtD
Trametinib—Vomiting—Sorafenib—thyroid cancer	0.000451	0.00109	CcSEcCtD
Trametinib—Abdominal pain upper—Doxorubicin—thyroid cancer	0.000451	0.00109	CcSEcCtD
Trametinib—Hypokalaemia—Doxorubicin—thyroid cancer	0.000449	0.00109	CcSEcCtD
Trametinib—Rash—Sorafenib—thyroid cancer	0.000447	0.00108	CcSEcCtD
Trametinib—Dermatitis—Sorafenib—thyroid cancer	0.000447	0.00108	CcSEcCtD
Trametinib—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	0.000444	0.00107	CcSEcCtD
Trametinib—Headache—Sorafenib—thyroid cancer	0.000444	0.00107	CcSEcCtD
Trametinib—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.000435	0.00105	CcSEcCtD
Trametinib—Neutropenia—Epirubicin—thyroid cancer	0.000431	0.00104	CcSEcCtD
Trametinib—Nausea—Sorafenib—thyroid cancer	0.000421	0.00102	CcSEcCtD
Trametinib—Pancreatitis—Doxorubicin—thyroid cancer	0.000418	0.00101	CcSEcCtD
Trametinib—Hyperglycaemia—Epirubicin—thyroid cancer	0.000416	0.00101	CcSEcCtD
Trametinib—Infestation NOS—Epirubicin—thyroid cancer	0.000411	0.000994	CcSEcCtD
Trametinib—Infestation—Epirubicin—thyroid cancer	0.000411	0.000994	CcSEcCtD
Trametinib—Renal failure—Epirubicin—thyroid cancer	0.000404	0.000977	CcSEcCtD
Trametinib—Stomatitis—Epirubicin—thyroid cancer	0.000401	0.000969	CcSEcCtD
Trametinib—Urinary tract infection—Epirubicin—thyroid cancer	0.000399	0.000966	CcSEcCtD
Trametinib—Neutropenia—Doxorubicin—thyroid cancer	0.000399	0.000965	CcSEcCtD
Trametinib—Haematuria—Epirubicin—thyroid cancer	0.000392	0.000948	CcSEcCtD
Trametinib—Epistaxis—Epirubicin—thyroid cancer	0.000388	0.000938	CcSEcCtD
Trametinib—Hyperglycaemia—Doxorubicin—thyroid cancer	0.000385	0.000931	CcSEcCtD
Trametinib—Infestation NOS—Doxorubicin—thyroid cancer	0.00038	0.00092	CcSEcCtD
Trametinib—Infestation—Doxorubicin—thyroid cancer	0.00038	0.00092	CcSEcCtD
Trametinib—Bradycardia—Epirubicin—thyroid cancer	0.000376	0.000909	CcSEcCtD
Trametinib—Renal failure—Doxorubicin—thyroid cancer	0.000374	0.000904	CcSEcCtD
Trametinib—Haemoglobin—Epirubicin—thyroid cancer	0.000371	0.000897	CcSEcCtD
Trametinib—Stomatitis—Doxorubicin—thyroid cancer	0.000371	0.000897	CcSEcCtD
Trametinib—Urinary tract infection—Doxorubicin—thyroid cancer	0.00037	0.000894	CcSEcCtD
Trametinib—Haemorrhage—Epirubicin—thyroid cancer	0.000369	0.000892	CcSEcCtD
Trametinib—Urinary tract disorder—Epirubicin—thyroid cancer	0.000364	0.000881	CcSEcCtD
Trametinib—Oedema peripheral—Epirubicin—thyroid cancer	0.000363	0.000879	CcSEcCtD
Trametinib—Haematuria—Doxorubicin—thyroid cancer	0.000363	0.000877	CcSEcCtD
Trametinib—Connective tissue disorder—Epirubicin—thyroid cancer	0.000362	0.000877	CcSEcCtD
Trametinib—Urethral disorder—Epirubicin—thyroid cancer	0.000362	0.000875	CcSEcCtD
Trametinib—Epistaxis—Doxorubicin—thyroid cancer	0.000359	0.000868	CcSEcCtD
Trametinib—Bradycardia—Doxorubicin—thyroid cancer	0.000347	0.000841	CcSEcCtD
Trametinib—Eye disorder—Epirubicin—thyroid cancer	0.000345	0.000834	CcSEcCtD
Trametinib—Haemoglobin—Doxorubicin—thyroid cancer	0.000343	0.00083	CcSEcCtD
Trametinib—Cardiac disorder—Epirubicin—thyroid cancer	0.000342	0.000828	CcSEcCtD
Trametinib—Haemorrhage—Doxorubicin—thyroid cancer	0.000341	0.000826	CcSEcCtD
Trametinib—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000337	0.000815	CcSEcCtD
Trametinib—Oedema peripheral—Doxorubicin—thyroid cancer	0.000336	0.000813	CcSEcCtD
Trametinib—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000335	0.000811	CcSEcCtD
Trametinib—Angiopathy—Epirubicin—thyroid cancer	0.000335	0.00081	CcSEcCtD
Trametinib—Urethral disorder—Doxorubicin—thyroid cancer	0.000335	0.000809	CcSEcCtD
Trametinib—Mediastinal disorder—Epirubicin—thyroid cancer	0.000332	0.000804	CcSEcCtD
Trametinib—Chills—Epirubicin—thyroid cancer	0.000331	0.000801	CcSEcCtD
Trametinib—Arrhythmia—Epirubicin—thyroid cancer	0.00033	0.000797	CcSEcCtD
Trametinib—Mental disorder—Epirubicin—thyroid cancer	0.000323	0.000782	CcSEcCtD
Trametinib—Erythema—Epirubicin—thyroid cancer	0.000321	0.000777	CcSEcCtD
Trametinib—Malnutrition—Epirubicin—thyroid cancer	0.000321	0.000777	CcSEcCtD
Trametinib—Eye disorder—Doxorubicin—thyroid cancer	0.000319	0.000772	CcSEcCtD
Trametinib—Cardiac disorder—Doxorubicin—thyroid cancer	0.000317	0.000766	CcSEcCtD
Trametinib—Dysgeusia—Epirubicin—thyroid cancer	0.000314	0.000761	CcSEcCtD
Trametinib—Back pain—Epirubicin—thyroid cancer	0.000311	0.000751	CcSEcCtD
Trametinib—Angiopathy—Doxorubicin—thyroid cancer	0.00031	0.000749	CcSEcCtD
Trametinib—Muscle spasms—Epirubicin—thyroid cancer	0.000309	0.000747	CcSEcCtD
Trametinib—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000308	0.000744	CcSEcCtD
Trametinib—Chills—Doxorubicin—thyroid cancer	0.000306	0.000741	CcSEcCtD
Trametinib—Arrhythmia—Doxorubicin—thyroid cancer	0.000305	0.000738	CcSEcCtD
Trametinib—Vision blurred—Epirubicin—thyroid cancer	0.000303	0.000732	CcSEcCtD
Trametinib—Mental disorder—Doxorubicin—thyroid cancer	0.000299	0.000723	CcSEcCtD
Trametinib—Malnutrition—Doxorubicin—thyroid cancer	0.000297	0.000719	CcSEcCtD
Trametinib—Erythema—Doxorubicin—thyroid cancer	0.000297	0.000719	CcSEcCtD
Trametinib—Anaemia—Epirubicin—thyroid cancer	0.000297	0.000718	CcSEcCtD
Trametinib—Dysgeusia—Doxorubicin—thyroid cancer	0.000291	0.000704	CcSEcCtD
Trametinib—Leukopenia—Epirubicin—thyroid cancer	0.000287	0.000695	CcSEcCtD
Trametinib—Back pain—Doxorubicin—thyroid cancer	0.000287	0.000695	CcSEcCtD
Trametinib—Muscle spasms—Doxorubicin—thyroid cancer	0.000286	0.000691	CcSEcCtD
Trametinib—Cough—Epirubicin—thyroid cancer	0.00028	0.000678	CcSEcCtD
Trametinib—Vision blurred—Doxorubicin—thyroid cancer	0.00028	0.000677	CcSEcCtD
Trametinib—Hypertension—Epirubicin—thyroid cancer	0.000277	0.000671	CcSEcCtD
Trametinib—Anaemia—Doxorubicin—thyroid cancer	0.000275	0.000664	CcSEcCtD
Trametinib—Arthralgia—Epirubicin—thyroid cancer	0.000273	0.000661	CcSEcCtD
Trametinib—Myalgia—Epirubicin—thyroid cancer	0.000273	0.000661	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000271	0.000657	CcSEcCtD
Trametinib—Dry mouth—Epirubicin—thyroid cancer	0.000267	0.000647	CcSEcCtD
Trametinib—Leukopenia—Doxorubicin—thyroid cancer	0.000266	0.000643	CcSEcCtD
Trametinib—Oedema—Epirubicin—thyroid cancer	0.000262	0.000634	CcSEcCtD
Trametinib—Infection—Epirubicin—thyroid cancer	0.00026	0.00063	CcSEcCtD
Trametinib—Cough—Doxorubicin—thyroid cancer	0.000259	0.000627	CcSEcCtD
Trametinib—Nervous system disorder—Epirubicin—thyroid cancer	0.000257	0.000622	CcSEcCtD
Trametinib—Thrombocytopenia—Epirubicin—thyroid cancer	0.000257	0.000621	CcSEcCtD
Trametinib—Hypertension—Doxorubicin—thyroid cancer	0.000257	0.000621	CcSEcCtD
Trametinib—Skin disorder—Epirubicin—thyroid cancer	0.000255	0.000616	CcSEcCtD
Trametinib—Hyperhidrosis—Epirubicin—thyroid cancer	0.000253	0.000613	CcSEcCtD
Trametinib—Myalgia—Doxorubicin—thyroid cancer	0.000253	0.000612	CcSEcCtD
Trametinib—Arthralgia—Doxorubicin—thyroid cancer	0.000253	0.000612	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000251	0.000608	CcSEcCtD
Trametinib—Dry mouth—Doxorubicin—thyroid cancer	0.000247	0.000599	CcSEcCtD
Trametinib—Oedema—Doxorubicin—thyroid cancer	0.000242	0.000587	CcSEcCtD
Trametinib—Infection—Doxorubicin—thyroid cancer	0.000241	0.000583	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000239	0.000578	CcSEcCtD
Trametinib—Nervous system disorder—Doxorubicin—thyroid cancer	0.000238	0.000575	CcSEcCtD
Trametinib—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000237	0.000574	CcSEcCtD
Trametinib—Insomnia—Epirubicin—thyroid cancer	0.000237	0.000573	CcSEcCtD
Trametinib—Skin disorder—Doxorubicin—thyroid cancer	0.000236	0.00057	CcSEcCtD
Trametinib—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000234	0.000567	CcSEcCtD
Trametinib—Decreased appetite—Epirubicin—thyroid cancer	0.000228	0.000551	CcSEcCtD
Trametinib—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000226	0.000547	CcSEcCtD
Trametinib—Fatigue—Epirubicin—thyroid cancer	0.000226	0.000547	CcSEcCtD
Trametinib—Constipation—Epirubicin—thyroid cancer	0.000224	0.000542	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000221	0.000535	CcSEcCtD
Trametinib—Insomnia—Doxorubicin—thyroid cancer	0.000219	0.000531	CcSEcCtD
Trametinib—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000214	0.000518	CcSEcCtD
Trametinib—Decreased appetite—Doxorubicin—thyroid cancer	0.000211	0.00051	CcSEcCtD
Trametinib—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000209	0.000506	CcSEcCtD
Trametinib—Fatigue—Doxorubicin—thyroid cancer	0.000209	0.000506	CcSEcCtD
Trametinib—Constipation—Doxorubicin—thyroid cancer	0.000207	0.000502	CcSEcCtD
Trametinib—Abdominal pain—Epirubicin—thyroid cancer	0.000207	0.000501	CcSEcCtD
Trametinib—Body temperature increased—Epirubicin—thyroid cancer	0.000207	0.000501	CcSEcCtD
Trametinib—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000198	0.00048	CcSEcCtD
Trametinib—Abdominal pain—Doxorubicin—thyroid cancer	0.000192	0.000464	CcSEcCtD
Trametinib—Body temperature increased—Doxorubicin—thyroid cancer	0.000192	0.000464	CcSEcCtD
Trametinib—Asthenia—Epirubicin—thyroid cancer	0.000188	0.000455	CcSEcCtD
Trametinib—Pruritus—Epirubicin—thyroid cancer	0.000185	0.000449	CcSEcCtD
Trametinib—Diarrhoea—Epirubicin—thyroid cancer	0.000179	0.000434	CcSEcCtD
Trametinib—Asthenia—Doxorubicin—thyroid cancer	0.000174	0.000421	CcSEcCtD
Trametinib—Dizziness—Epirubicin—thyroid cancer	0.000173	0.000419	CcSEcCtD
Trametinib—Pruritus—Doxorubicin—thyroid cancer	0.000172	0.000415	CcSEcCtD
Trametinib—Vomiting—Epirubicin—thyroid cancer	0.000167	0.000403	CcSEcCtD
Trametinib—Diarrhoea—Doxorubicin—thyroid cancer	0.000166	0.000401	CcSEcCtD
Trametinib—Rash—Epirubicin—thyroid cancer	0.000165	0.0004	CcSEcCtD
Trametinib—Dermatitis—Epirubicin—thyroid cancer	0.000165	0.000399	CcSEcCtD
Trametinib—Headache—Epirubicin—thyroid cancer	0.000164	0.000397	CcSEcCtD
Trametinib—Dizziness—Doxorubicin—thyroid cancer	0.00016	0.000388	CcSEcCtD
Trametinib—Nausea—Epirubicin—thyroid cancer	0.000156	0.000377	CcSEcCtD
Trametinib—Vomiting—Doxorubicin—thyroid cancer	0.000154	0.000373	CcSEcCtD
Trametinib—Rash—Doxorubicin—thyroid cancer	0.000153	0.00037	CcSEcCtD
Trametinib—Dermatitis—Doxorubicin—thyroid cancer	0.000153	0.00037	CcSEcCtD
Trametinib—Headache—Doxorubicin—thyroid cancer	0.000152	0.000368	CcSEcCtD
Trametinib—Nausea—Doxorubicin—thyroid cancer	0.000144	0.000348	CcSEcCtD
Trametinib—MAP2K1—Disease—TPR—thyroid cancer	0.000107	0.000244	CbGpPWpGaD
Trametinib—MAP2K1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	0.000106	0.000243	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR—KRAS—thyroid cancer	0.000106	0.000242	CbGpPWpGaD
Trametinib—MAP2K2—MAPK Signaling Pathway—TP53—thyroid cancer	0.000106	0.000242	CbGpPWpGaD
Trametinib—MAP2K2—Insulin Signaling—HRAS—thyroid cancer	0.000105	0.000241	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—SST—thyroid cancer	0.000105	0.00024	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PRKAR1A—thyroid cancer	0.000105	0.00024	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—KRAS—thyroid cancer	0.000105	0.00024	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signal transduction—HRAS—thyroid cancer	0.000105	0.000239	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by PDGF—KRAS—thyroid cancer	0.000105	0.000239	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signaling of activated FGFR—HRAS—thyroid cancer	0.000104	0.000238	CbGpPWpGaD
Trametinib—MAP2K2—EGF/EGFR Signaling Pathway—HRAS—thyroid cancer	0.000104	0.000238	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR—HRAS—thyroid cancer	0.000104	0.000238	CbGpPWpGaD
Trametinib—MAP2K2—Regulation of toll-like receptor signaling pathway—AKT1—thyroid cancer	0.000104	0.000238	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB2—HRAS—thyroid cancer	0.000104	0.000237	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—NDUFA13—thyroid cancer	0.000103	0.000236	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 signaling—HRAS—thyroid cancer	0.000103	0.000236	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by SCF-KIT—AKT1—thyroid cancer	0.000103	0.000235	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB4—HRAS—thyroid cancer	0.000103	0.000235	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TCF7L1—thyroid cancer	0.000102	0.000233	CbGpPWpGaD
Trametinib—MAP2K1—TGF-beta Signaling Pathway—AKT1—thyroid cancer	0.000102	0.000232	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—PTEN—thyroid cancer	0.000101	0.000232	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—CALCA—thyroid cancer	0.000101	0.000231	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—KRAS—thyroid cancer	0.000101	0.000231	CbGpPWpGaD
Trametinib—MAP2K2—BDNF signaling pathway—AKT1—thyroid cancer	0.000101	0.000231	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	0.000101	0.00023	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MEN1—thyroid cancer	0.0001	0.000229	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—TP53—thyroid cancer	9.91e-05	0.000226	CbGpPWpGaD
Trametinib—MAP2K1—Insulin Signaling—HRAS—thyroid cancer	9.86e-05	0.000225	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—SST—thyroid cancer	9.85e-05	0.000225	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signaling of activated FGFR—AKT1—thyroid cancer	9.85e-05	0.000225	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signal transduction—HRAS—thyroid cancer	9.81e-05	0.000224	CbGpPWpGaD
Trametinib—MAP2K2—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	9.79e-05	0.000224	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR—HRAS—thyroid cancer	9.76e-05	0.000223	CbGpPWpGaD
Trametinib—MAP2K1—EGF/EGFR Signaling Pathway—HRAS—thyroid cancer	9.76e-05	0.000223	CbGpPWpGaD
Trametinib—MAP2K1—Regulation of toll-like receptor signaling pathway—AKT1—thyroid cancer	9.74e-05	0.000222	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CHST14—thyroid cancer	9.73e-05	0.000222	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 interactions—HRAS—thyroid cancer	9.72e-05	0.000222	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR in disease—HRAS—thyroid cancer	9.72e-05	0.000222	CbGpPWpGaD
Trametinib—MAP2K2—Fc epsilon receptor (FCERI) signaling—HRAS—thyroid cancer	9.72e-05	0.000222	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB2—HRAS—thyroid cancer	9.71e-05	0.000222	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB4—AKT1—thyroid cancer	9.69e-05	0.000221	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 signaling—HRAS—thyroid cancer	9.66e-05	0.000221	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR—HRAS—thyroid cancer	9.63e-05	0.00022	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by SCF-KIT—AKT1—thyroid cancer	9.63e-05	0.00022	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—PPARG—thyroid cancer	9.55e-05	0.000218	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR in Cancer—HRAS—thyroid cancer	9.55e-05	0.000218	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by PDGF—HRAS—thyroid cancer	9.5e-05	0.000217	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—PTEN—thyroid cancer	9.49e-05	0.000217	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—CALCA—thyroid cancer	9.48e-05	0.000217	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—KRAS—thyroid cancer	9.47e-05	0.000216	CbGpPWpGaD
Trametinib—MAP2K1—BDNF signaling pathway—AKT1—thyroid cancer	9.47e-05	0.000216	CbGpPWpGaD
Trametinib—MAP2K2—Insulin Signaling—AKT1—thyroid cancer	9.3e-05	0.000212	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signal transduction—AKT1—thyroid cancer	9.26e-05	0.000211	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signaling of activated FGFR—AKT1—thyroid cancer	9.21e-05	0.00021	CbGpPWpGaD
Trametinib—MAP2K2—EGF/EGFR Signaling Pathway—AKT1—thyroid cancer	9.21e-05	0.00021	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR—AKT1—thyroid cancer	9.21e-05	0.00021	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—NRAS—thyroid cancer	9.2e-05	0.00021	CbGpPWpGaD
Trametinib—MAP2K2—Focal Adhesion—HRAS—thyroid cancer	9.18e-05	0.00021	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—CDK1—thyroid cancer	9.17e-05	0.00021	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB2—AKT1—thyroid cancer	9.17e-05	0.000209	CbGpPWpGaD
Trametinib—MAP2K1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	9.16e-05	0.000209	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 signaling—AKT1—thyroid cancer	9.12e-05	0.000208	CbGpPWpGaD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—HRAS—thyroid cancer	9.09e-05	0.000208	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 interactions—HRAS—thyroid cancer	9.09e-05	0.000208	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR in disease—HRAS—thyroid cancer	9.09e-05	0.000208	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB4—AKT1—thyroid cancer	9.07e-05	0.000207	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—NRAS—thyroid cancer	9.05e-05	0.000207	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR—HRAS—thyroid cancer	9.01e-05	0.000206	CbGpPWpGaD
Trametinib—MAP2K2—MAPK Signaling Pathway—AKT1—thyroid cancer	8.95e-05	0.000204	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	8.95e-05	0.000204	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—PPARG—thyroid cancer	8.93e-05	0.000204	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—HRAS—thyroid cancer	8.93e-05	0.000204	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by PDGF—HRAS—thyroid cancer	8.89e-05	0.000203	CbGpPWpGaD
Trametinib—CYP3A4—Biological oxidations—RXRA—thyroid cancer	8.89e-05	0.000203	CbGpPWpGaD
Trametinib—MAP2K1—Insulin Signaling—AKT1—thyroid cancer	8.7e-05	0.000199	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signal transduction—AKT1—thyroid cancer	8.66e-05	0.000198	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR—AKT1—thyroid cancer	8.62e-05	0.000197	CbGpPWpGaD
Trametinib—MAP2K1—EGF/EGFR Signaling Pathway—AKT1—thyroid cancer	8.62e-05	0.000197	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—NRAS—thyroid cancer	8.61e-05	0.000197	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—HRAS—thyroid cancer	8.61e-05	0.000197	CbGpPWpGaD
Trametinib—MAP2K1—Focal Adhesion—HRAS—thyroid cancer	8.59e-05	0.000196	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—CDK1—thyroid cancer	8.58e-05	0.000196	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 interactions—AKT1—thyroid cancer	8.58e-05	0.000196	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR in disease—AKT1—thyroid cancer	8.58e-05	0.000196	CbGpPWpGaD
Trametinib—MAP2K2—Fc epsilon receptor (FCERI) signaling—AKT1—thyroid cancer	8.58e-05	0.000196	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB2—AKT1—thyroid cancer	8.58e-05	0.000196	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CALCA—thyroid cancer	8.55e-05	0.000195	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 signaling—AKT1—thyroid cancer	8.53e-05	0.000195	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR—AKT1—thyroid cancer	8.5e-05	0.000194	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—NRAS—thyroid cancer	8.47e-05	0.000193	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR in Cancer—AKT1—thyroid cancer	8.43e-05	0.000193	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by PDGF—AKT1—thyroid cancer	8.39e-05	0.000192	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CDK1—thyroid cancer	8.38e-05	0.000191	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—AKT1—thyroid cancer	8.37e-05	0.000191	CbGpPWpGaD
Trametinib—MAP2K2—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	8.32e-05	0.00019	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—NRAS—thyroid cancer	8.19e-05	0.000187	CbGpPWpGaD
Trametinib—MAP2K2—Focal Adhesion—AKT1—thyroid cancer	8.11e-05	0.000185	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IFNA2—thyroid cancer	8.06e-05	0.000184	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—HRAS—thyroid cancer	8.05e-05	0.000184	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR in disease—AKT1—thyroid cancer	8.03e-05	0.000183	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 interactions—AKT1—thyroid cancer	8.03e-05	0.000183	CbGpPWpGaD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—AKT1—thyroid cancer	8.03e-05	0.000183	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CALCA—thyroid cancer	8e-05	0.000183	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TSHR—thyroid cancer	8e-05	0.000183	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR—AKT1—thyroid cancer	7.96e-05	0.000182	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—KRAS—thyroid cancer	7.92e-05	0.000181	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—AKT1—thyroid cancer	7.89e-05	0.00018	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PRKAR1A—thyroid cancer	7.87e-05	0.00018	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by PDGF—AKT1—thyroid cancer	7.85e-05	0.000179	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CDK1—thyroid cancer	7.84e-05	0.000179	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—HPGD—thyroid cancer	7.84e-05	0.000179	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—KRAS—thyroid cancer	7.79e-05	0.000178	CbGpPWpGaD
Trametinib—MAP2K1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	7.78e-05	0.000178	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CDK1—thyroid cancer	7.74e-05	0.000177	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—NRAS—thyroid cancer	7.66e-05	0.000175	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—AKT1—thyroid cancer	7.6e-05	0.000174	CbGpPWpGaD
Trametinib—MAP2K1—Focal Adhesion—AKT1—thyroid cancer	7.59e-05	0.000173	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	7.55e-05	0.000173	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IFNA2—thyroid cancer	7.54e-05	0.000172	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MEN1—thyroid cancer	7.52e-05	0.000172	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TSHR—thyroid cancer	7.48e-05	0.000171	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—KRAS—thyroid cancer	7.41e-05	0.000169	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PRKAR1A—thyroid cancer	7.36e-05	0.000168	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—KRAS—thyroid cancer	7.29e-05	0.000166	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CDK1—thyroid cancer	7.24e-05	0.000165	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—AKT1—thyroid cancer	7.11e-05	0.000162	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—KRAS—thyroid cancer	7.05e-05	0.000161	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MEN1—thyroid cancer	7.03e-05	0.000161	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PTCH1—thyroid cancer	6.8e-05	0.000155	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—HRAS—thyroid cancer	6.73e-05	0.000154	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—NRG1—thyroid cancer	6.73e-05	0.000154	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—HRAS—thyroid cancer	6.62e-05	0.000151	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—KRAS—thyroid cancer	6.59e-05	0.000151	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—MINPP1—thyroid cancer	6.53e-05	0.000149	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PTCH1—thyroid cancer	6.36e-05	0.000145	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	6.36e-05	0.000145	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—HRAS—thyroid cancer	6.3e-05	0.000144	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—NRG1—thyroid cancer	6.29e-05	0.000144	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—SST—thyroid cancer	6.22e-05	0.000142	CbGpPWpGaD
Trametinib—MAP2K2—Disease—NRG1—thyroid cancer	6.21e-05	0.000142	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—HRAS—thyroid cancer	6.19e-05	0.000141	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—HRAS—thyroid cancer	5.99e-05	0.000137	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CALCA—thyroid cancer	5.99e-05	0.000137	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—AKT1—thyroid cancer	5.85e-05	0.000134	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—NRAS—thyroid cancer	5.84e-05	0.000133	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—SST—thyroid cancer	5.82e-05	0.000133	CbGpPWpGaD
Trametinib—MAP2K1—Disease—NRG1—thyroid cancer	5.81e-05	0.000133	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—PTEN—thyroid cancer	5.79e-05	0.000132	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—HRAS—thyroid cancer	5.61e-05	0.000128	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CALCA—thyroid cancer	5.6e-05	0.000128	CbGpPWpGaD
Trametinib—MAP2K2—Disease—TERT—thyroid cancer	5.58e-05	0.000127	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—NDUFA13—thyroid cancer	5.55e-05	0.000127	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—AKT1—thyroid cancer	5.47e-05	0.000125	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—NRAS—thyroid cancer	5.47e-05	0.000125	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CDK1—thyroid cancer	5.42e-05	0.000124	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—PTEN—thyroid cancer	5.41e-05	0.000124	CbGpPWpGaD
Trametinib—MAP2K2—Disease—HIF1A—thyroid cancer	5.33e-05	0.000122	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CHST14—thyroid cancer	5.22e-05	0.000119	CbGpPWpGaD
Trametinib—MAP2K1—Disease—TERT—thyroid cancer	5.22e-05	0.000119	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—NRAS—thyroid cancer	5.16e-05	0.000118	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CDK1—thyroid cancer	5.07e-05	0.000116	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—KRAS—thyroid cancer	5.03e-05	0.000115	CbGpPWpGaD
Trametinib—MAP2K1—Disease—HIF1A—thyroid cancer	4.99e-05	0.000114	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—NRAS—thyroid cancer	4.83e-05	0.00011	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—KRAS—thyroid cancer	4.71e-05	0.000107	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—TPR—thyroid cancer	4.5e-05	0.000103	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—KRAS—thyroid cancer	4.44e-05	0.000101	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PRKAR1A—thyroid cancer	4.43e-05	0.000101	CbGpPWpGaD
Trametinib—MAP2K2—Disease—BRAF—thyroid cancer	4.42e-05	0.000101	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—NRG1—thyroid cancer	4.35e-05	9.93e-05	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—HRAS—thyroid cancer	4.28e-05	9.77e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—HPGD—thyroid cancer	4.21e-05	9.61e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—KRAS—thyroid cancer	4.16e-05	9.49e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—BRAF—thyroid cancer	4.13e-05	9.44e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NRG1—thyroid cancer	4.07e-05	9.29e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	4.01e-05	9.17e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—HRAS—thyroid cancer	4e-05	9.14e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TERT—thyroid cancer	3.91e-05	8.92e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—HRAS—thyroid cancer	3.78e-05	8.62e-05	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—AKT1—thyroid cancer	3.78e-05	8.62e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—HIF1A—thyroid cancer	3.73e-05	8.53e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TERT—thyroid cancer	3.65e-05	8.35e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PTGS2—thyroid cancer	3.57e-05	8.15e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—HRAS—thyroid cancer	3.53e-05	8.07e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—AKT1—thyroid cancer	3.53e-05	8.07e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—HIF1A—thyroid cancer	3.49e-05	7.98e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—SLC5A5—thyroid cancer	3.37e-05	7.7e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—PTEN—thyroid cancer	3.37e-05	7.7e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PTGS2—thyroid cancer	3.34e-05	7.62e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—AKT1—thyroid cancer	3.33e-05	7.62e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—NRAS—thyroid cancer	3.29e-05	7.52e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	3.16e-05	7.21e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PTEN—thyroid cancer	3.15e-05	7.2e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—AKT1—thyroid cancer	3.12e-05	7.12e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PTEN—thyroid cancer	3.11e-05	7.11e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—BRAF—thyroid cancer	3.09e-05	7.06e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—NRAS—thyroid cancer	3.08e-05	7.03e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—NRAS—thyroid cancer	3.01e-05	6.87e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PTEN—thyroid cancer	2.91e-05	6.65e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—BRAF—thyroid cancer	2.89e-05	6.61e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—RXRA—thyroid cancer	2.83e-05	6.47e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—KRAS—thyroid cancer	2.83e-05	6.47e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—NRAS—thyroid cancer	2.81e-05	6.42e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—NRAS—thyroid cancer	2.78e-05	6.34e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.75e-05	6.29e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—KRAS—thyroid cancer	2.65e-05	6.05e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—NRAS—thyroid cancer	2.6e-05	5.93e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—KRAS—thyroid cancer	2.59e-05	5.91e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—KRAS—thyroid cancer	2.42e-05	5.53e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—TPR—thyroid cancer	2.42e-05	5.52e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—HRAS—thyroid cancer	2.41e-05	5.5e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—KRAS—thyroid cancer	2.39e-05	5.46e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	2.38e-05	5.43e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CCND1—thyroid cancer	2.26e-05	5.16e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—HRAS—thyroid cancer	2.25e-05	5.14e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—KRAS—thyroid cancer	2.23e-05	5.1e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—HRAS—thyroid cancer	2.2e-05	5.02e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PTEN—thyroid cancer	2.18e-05	4.98e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—AKT1—thyroid cancer	2.13e-05	4.85e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CCND1—thyroid cancer	2.11e-05	4.82e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—HRAS—thyroid cancer	2.06e-05	4.7e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PTEN—thyroid cancer	2.04e-05	4.66e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—HRAS—thyroid cancer	2.03e-05	4.64e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—AKT1—thyroid cancer	1.99e-05	4.54e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—NRAS—thyroid cancer	1.94e-05	4.44e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—AKT1—thyroid cancer	1.94e-05	4.44e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—HRAS—thyroid cancer	1.9e-05	4.34e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NRAS—thyroid cancer	1.82e-05	4.15e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—AKT1—thyroid cancer	1.82e-05	4.15e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—SLC5A5—thyroid cancer	1.81e-05	4.13e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—AKT1—thyroid cancer	1.79e-05	4.1e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PPARG—thyroid cancer	1.79e-05	4.08e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—AKT1—thyroid cancer	1.68e-05	3.83e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—KRAS—thyroid cancer	1.67e-05	3.82e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—KRAS—thyroid cancer	1.57e-05	3.57e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—RXRA—thyroid cancer	1.52e-05	3.47e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TP53—thyroid cancer	1.49e-05	3.4e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—HRAS—thyroid cancer	1.42e-05	3.25e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PTGS2—thyroid cancer	1.41e-05	3.21e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TP53—thyroid cancer	1.39e-05	3.18e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—HRAS—thyroid cancer	1.33e-05	3.04e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—AKT1—thyroid cancer	1.26e-05	2.87e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PTEN—thyroid cancer	1.23e-05	2.8e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—AKT1—thyroid cancer	1.17e-05	2.68e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PPARG—thyroid cancer	9.6e-06	2.19e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PTGS2—thyroid cancer	7.55e-06	1.72e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—AKT1—thyroid cancer	7.07e-06	1.61e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PTEN—thyroid cancer	6.58e-06	1.5e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—AKT1—thyroid cancer	3.79e-06	8.67e-06	CbGpPWpGaD
